

AMENDMENT NO. 7 TO MMCAP INFUSE AGREEMENT NO. MMS1900151

THIS AMENDMENT NO. 7 ("**Amendment**") to MMS1900151 and its amendments ("**Agreement**") is entered into on the date all required signatures are obtained for this document and is by and between the State of Minnesota acting through its Commissioner of Administration ("**Minnesota**") on behalf of MMCAP Infuse ("**MMCAP Infuse**") and McKesson Medical Surgical Inc., McKesson Medical-Surgical Minnesota Supply Inc. and McKesson Medical-Surgical Government Solutions LLC, whose designated business address of 9954 Mayland Avenue, Suite 4000, Henrico, VA 23233 ("**Vendor**").

RECITALS

WHEREAS, MMCAP Infuse and Vendor have agreed to certain changes in the terms and conditions set forth in the Agreement and have agreed to amend the Agreement to reflect said changes;

WHEREAS, besides the terms and conditions of the Agreement amended in this Amendment, the Agreement remains in full force and effect; and

NOW, THEREFORE, the parties acknowledge and hereby agree that the Agreement shall be amended as follows:

Capitalized Terms; Definitions; Conditions. The Agreement and Amendments shall be read together as one document. Any capitalized terms used in the Amendment that are defined in the Agreement will have the same meaning(s) when used herein, unless the context clearly requires otherwise. To the extent there shall exist a conflict between the Agreement and this Amendment, the terms of this Amendment will control. Unless otherwise clearly altered, modified, deleted, or amended otherwise, the terms of the Agreement will continue in their entirety and govern the contractual relationship between Vendor and MMCAP Infuse.

In this Amendment, changes to pre-existing Agreement language will use ~~strike through~~ for deletions and underlining for insertions.

Modifications


Revision 1: Line 2 of the *Contract Term* of the Agreement will be revised as follows:

2. **Expiration Date:** ~~March 31, 2025~~ July 31, 2025, or until all obligations have been satisfactorily fulfilled as determined by MMCAP Infuse, whichever occurs first.

Revision 2: Exhibit 1 Influenza Products and Pricing for the 2025-2026 season, attached and incorporated to this Amendment, will be added as a part of **Attachment G** to the Agreement.


**VENDOR: MCKESSON MEDICAL SURGICAL INC.,
MCKESSON MEDICAL-SURGICAL MINNESOTA SUPPLY
INC. AND MCKESSON MEDICAL-SURGICAL
GOVERNMENT SOLUTIONS LLC.**

The Vendor certified that the appropriate person(s) have executed this Amendment on behalf of the Vendor as required and by applicable articles, bylaws, resolutions, or ordinances.

Name: David McDade
Signature: 
Title: VP/GM, Government Solutions
Date: December 20, 2024

STATE OF MINNESOTA FOR MMCAP INFUSE

In accordance with Minn. Stat. § 16C.03, subd. 3

Name: Don Sis
Signature: 
Date: 12/20/2024

COMMISSIONER OF ADMINISTRATION

In accordance with Minn. Stat. § 16C.05, subd. 2

Name: Michelle Korpela
Signature: 
Date: 12/20/2024

EXHIBIT 1**Attachment G****Influenza Products and Pricing for the 2025-2026 Season**

Effective: **December 20th, 2024** or when fully signed, whichever is later.

1. Ordering Mechanisms:

- a. Online: <https://mms.mckesson.com/portal/index.mck>
- b. Phone: (800) 328-8111, Option 1
- c. Email: government.customerservice@mckesson.com

2. Table 1: Products for the 2024-2025 Influenza season.

Mfr. Name	Product Name	Container Type, Product Age Indication	Pack Size	MMCAP Infuse Price per Pack (Prices do not include FET)
AstraZeneca	FluMist NDC 66019-0112-10	0.2ml Nasal Sprayer; 2 to 49 years	Pack of 10	\$213.70
GSK	Fluarix NDC 58160-0912-52	0.5ml prefilled syringes, 6 mo. & older	Pack of 10	\$184.24
GSK	Flulaval NDC 19515-0904-52	0.5ml prefilled syringes, 6 mo. & older	Pack of 10	\$184.24
Seqirus	Afluria NDC 33332-xxxx-xx	0.5ml prefilled syringes ; 3 years & older	Pack of 10	\$158.10
Seqirus	Afluria NDC 33332-xxxx-xx	5 ml MD vial ; 6 mo. & older	10-dose vial	\$158.10
Seqirus	Fluad NDC 70461-xxxx-xx	0.5ml prefilled syringes; 65 years & older	Pack of 10	\$660.79
Seqirus	Flucelvax NDC 70461-xxxx-xx	0.5ml prefilled syringes ; 6 mo. & older	Pack of 10	\$259.94
Seqirus	Flucelvax NDC 70461-xxxx-xx	5 ml MD vial ; 6 mo. & older	10-dose vial	\$246.80

NDCs shall be reconfirmed when provided by Suppliers. All prices listed are not inclusive of Federal Excise Tax of \$0.75/dose.

If the manufacturer requires a signed DEC form, the Member will sign and Vendor will offer contract pricing once all member locations have been rostered by the manufacturer. GSK contract prices in *Table 1* above require all ship-to locations to have a signed DEC form and eligibility confirmed in the manufacturer's system to receive MMCAP Infuse contract pricing. MMCAP Infuse Members should contact MMCAP Infuse to obtain a GSK DEC form if one has not already been completed. All ship-to locations must be rostered in the manufacturer system.

3. Additional Discounts.

Vendor is not offering any additional discounts.

4. Returned Goods/ Credits.Flu Vaccine Return Policy

Only customers who pre-book doses by April 15, 2025 for GSK and Seqirus, and receive their full pre-book on or before November 14, 2025, will have the right to return up to the designated percentage by supplier presentation of unopened products for the 2025-2026 influenza season according to the guidelines below:

- Member will receive a credit for eligible doses returned to McKesson between March 01, 2026, and April 30, 2026. Credit will be issued for use in the subsequent influenza season on or before December 31, 2026.

- Unopened vials or boxes must be returned to McKesson between March 01, 2026, and April 30, 2026, and in accordance with McKesson vaccine guidelines.
- Only unopened units (vials or boxes of pre-filled syringes) are eligible to be returned. Eligible quantities will be rounded down to the nearest whole number.

MMCAP Infuse Participating Facilities may return contracted purchased full pack quantities of product to Vendor via the following guidelines for credit. Contact Vendor’s Customer Care Team at 1-800-328-8111 for complete returns instructions.

Manufacturer	Return Eligibility
AstraZeneca	Up to 20% of doses are eligible for return
GSK	Up to 10% of doses are eligible for return
Seqirus	Up to 15% of doses are eligible for return

Contact the customer care team for further information. Vendor will supply a copy of its returned goods/credit policy to Members upon request.

Prebook Order form: 2025-2026 Prebook order form available from Vendor.